• 中国核心期刊数据库收录期刊
  • 中文科技期刊数据库收录期刊
  • 中国期刊全文数据库收录期刊
  • 中国学术期刊综合评价数据库统计源期刊等

快速检索引用检索图表检索高级检索

中国医药导刊 ›› 2025, Vol. 27 ›› Issue (4): 385-390.

• 临床医药 • 上一篇    下一篇

精细化临床药师主导模式药学干预对老年急性心肌梗死患者PCI术后DAPT依从性的影响

陈良1, 马祥连2, 张文菊2, 李宝2, 陈刚1*   

  1. 明光市人民医院临床药学室1,心血管内科2,安徽 明光 239400
  • 收稿日期:2024-12-17 修回日期:2025-03-13 出版日期:2025-04-28 发布日期:2025-04-28
  • 基金资助:

    安徽省滁州城市职业学院校级重点项目(2023zkzd05)

The Influence of Refined Clinical Pharmacist-Led Pharmaceutical Intervention on DAPT Compliance in Elderly Patients with Acute Myocardial Infarction after PCI

  1. Department of Clinical Pharmacy1 Department of Cardiovascular Medicine2
    Mingguang People's Hospital Anhui Mingguang 239400, China
  • Received:2024-12-17 Revised:2025-03-13 Online:2025-04-28 Published:2025-04-28

摘要:

目的:探讨精细化临床药师主导模式药学干预对老年急性心肌梗死(AMI)患者经皮冠状动脉介入(PCI)术后双联抗血小板治疗(DAPT)依从性的影响。方法:选取20231月至20243月我院收治的72PCI术后使用DAPT的老年AMI患者作为研究对象,采用随机数字表法分组,对照组(n=36)给予常规药学干预,研究组(n=36)在对照组基础上给予精细化临床药师主导模式药学干预。比较两组患者的用药依从性[药物知识评分(MKS)、药物依从性量表(MMAS-8)评分]、治疗结果[心脏超声(LVEF)、心电图(ECG)、肌钙蛋白(cTn)、B型尿钠肽(BNP)、全球急性冠脉事件登记(GRACE)评分、心肌梗死多维度量表(MIDAS)评分]、不良事件发生率以及患者满意度情况。结果:干预前,两组患者的MKSMMAS-8评分差异无统计学意义(P>0.05;干预后,两组患者MKSMMAS-8评分较干预前均有提高(P<0.05),且研究组高于对照组(P<0.05)。干预前,两组患者LVEFECGcTnBNPGRACE评分及MIDAS评分差异无统计学意义(P>0.05);干预后,两组患者LVEFECGcTnBNPGRACE评分及MIDAS评分较干预前均有改善(P<0.05),且研究组优于对照组(P<0.05)。研究组不良事件发生率(0%)低于对照组(11.11%)(P<0.05),患者满意度(97.22%)高于对照组(80.56%)(P<0.05)。结论:精细化临床药师主导模式药学干预可以提高老年AMI患者PCI术后DAPT依从性,从而有利于改善治疗结果。


关键词: 临床药师主导模式药学干预, 精细化, 老年患者, 急性心肌梗死, 经皮冠状动脉介入, 双联抗血小板治疗

Abstract:

Objective: To explore the effect of refined clinical pharmacist-led pharmaceutical intervention on the compliance of dual antiplatelet therapy DAPT in elderly patients with acute myocardial infarction AMI after percutaneous coronary intervention PCI.Methods: A total of 72 elderly AMI patients treated in our hospital from January 2023 to March 2024 who received DAPT after PCI were selected as the research subjects and were divided into the control group and the study group according to the random number table method.The control group n=36 received routine pharmaceutical intervention and the study group n=36 received refined clinical pharmacist-led pharmaceutical intervention on the basis of the control group. The medication adherence medication knowledge score MKS), Morisky medication adherence scale-8 MMAS-8 score], treatment outcomes cardiac ultrasound LVEF), electrocardiogram ECG), cardiac troponin cTn), B-type natriuretic peptide BNP), global registry of acute coronary events GRACE score myoeardial infarction dimensional assessment scale MIDAS score], incidence of adverse events and patient satisfaction of the two groups were compared.Results: Before intervention there was no statistically significant difference in MKS and MMAS-8 scores between the two groups P>0.05. After intervention both groups showed an improvement in MKS and MMAS-8 scores compared to those before intervention P<0.05), and the scores of the study group were higher than those of the control group P<0.05. Before intervention there was no statistically significant difference in LVEF ECG cTn BNP GRACE scores and MIDAS scores between the two groups P>0.05. After intervention the LVEF ECG cTn BNP GRACE scores and MIDAS scores in both groups improved compared to those before intervention P<0.05), and the study group was better than the control group P<0.05. The adverse event rate of the study group 0% was lower than that of the control group 11.11%) (P<0.05. The patient satisfaction rate of the study group 97.22% was higher than that of the control group 80.56%) (P<0.05.Conclusion: The refined clinical pharmacist-led pharmaceutical intervention can improve DAPT compliance in elderly AMI patients after PCI which is conducive to improving the treatment outcomes.


Key words:  , Clinical pharmacist-led pharmaceutical intervention , Refined , Elderly patients , Acute myocardial infarction , Percutaneous coronary intervention , Dual antiplatelet therapy

中图分类号: